• Integrating CMC, clinical, and regulatory strategies to accelerate early-to-mid stage development
• Building frameworks to enable scalability across diverse cell and gene therapy modalities
• Overcoming end-to-end value chain complexities in patient-specific material acquisition and processing
• Case study: Operationalizing personalized therapy at Genentech’s Hillsboro Individualized Therapies (HIT) facility
• Preparing technical operations for the next 5 years of CGT innovation and commercialization